ArticleInvestigative ophthalmology & visual science2011
Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.
Article in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- The HAT Inhibitor ISOX-DUAL Diminishes Ischemic Areas in a Mouse Model of Oxygen-Induced Retinopathy.Genes to cells : devoted to molecular & cellular mechanisms · 2025Article
- Optical Coherence Tomography Angiography Changes in Diabetic Macular Ischemia after Systemic Normobaric Oxygen Therapy.Journal of ophthalmic & vision research · 2025Article
- PERK Inhibition Suppresses Neovascularization and Protects Neurons During Ischemia-Induced Retinopathy.Investigative ophthalmology & visual science · 2023Article
- Retinal Oxygen Delivery and Metabolism Response to Hyperoxia During Bilateral Common Carotid Artery Occlusion in Rats.Investigative ophthalmology & visual science · 2022Article
- circFTO upregulates transforming growth factor-alpha through sponging miR-148a-3p to regulate high glucose-induced ARPE-19 cells injury.Bioengineered · 2022Article
- Mechanism of Neonatal Intestinal Injury Induced by Hyperoxia Therapy.Journal of immunology research · 2022Review
- A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke.Journal of neuroinflammation · 2018Review
- The progress of prophylactic treatment in retinopathy of prematurity.International journal of ophthalmology · 2018Review
- Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity.Pediatric research · 2017Article
- BH4-Mediated Enhancement of Endothelial Nitric Oxide Synthase Activity Reduces Hyperoxia-Induced Endothelial Damage and Preserves Vascular Integrity in the Neonate.Investigative ophthalmology & visual science · 2017Article
- Hydrogen Sulfide Contributes to Retinal Neovascularization in Ischemia-Induced Retinopathy.Investigative ophthalmology & visual science · 2016Article
- Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model.Journal of molecular neuroscience : MN · 2015Article
- TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization.Investigative ophthalmology & visual science · 2014Article
- Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.Investigative ophthalmology & visual science · 2013Article
- Endothelial tip cells in ocular angiogenesis: potential target for anti-angiogenesis therapy.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Review
- 17-Alpha-estradiol ameliorating oxygen-induced retinopathy in a murine model.Japanese journal of ophthalmology · 2012Article
- TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model.Investigative ophthalmology & visual science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy.
methodsHyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied.
resultsAdministration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes.
conclusionsHT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.